Braxia Scientific Corp. (BRAXF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Braxia Scientific Corp. (BRAXF) trades at $0.00 with AI Score 51/100 (Grade B). Braxia Scientific Corp. is a medical research company operating clinics that provide ketamine treatments for depression and related disorders. Market cap: $28,328, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for BRAXF: BRAXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BRAXF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BRAXF: 2/6 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Braxia Scientific Corp. (BRAXF) Healthcare & Pipeline Overview
Braxia Scientific Corp. is a Canadian healthcare company focused on advancing mental health treatment through its network of ketamine clinics and a dedicated research platform. It develops novel psychedelic-derived therapeutics and delivery methods for depression and related disorders, aiming to innovate within the rapidly evolving psychiatric pharmaceutical landscape.
What Is the Investment Thesis for BRAXF?
Braxia Scientific Corp. presents an investment thesis centered on its dual operational model: direct patient care through ketamine clinics and an intellectual property (IP) development platform for novel psychedelic therapeutics. The company operates in the growing mental healthcare market, specifically targeting depression and related disorders with ketamine treatments. Its gross margin of 9.1% indicates some operational efficiency in its service delivery, though the significant negative profit margin of -697.5% and negative free cash flow of $-0.00B highlight ongoing substantial investment in research and development and operational scaling. The company's beta of 1.31 suggests higher volatility compared to the broader market, typical for early-stage biotechnology firms. Key value drivers include the potential for expansion of its ketamine clinic network and the successful development and commercialization of its pipeline of ketamine and psilocybin derivatives. The IP platform aims to create proprietary psychedelic products and delivery methods, which could unlock significant market opportunities if regulatory approvals are secured. The long-term growth trajectory is tied to the evolving acceptance and regulatory framework for psychedelic-assisted therapies. However, the current financial performance necessitates careful consideration of capital requirements and the timeline to profitability.
Based on FMP financials and quantitative analysis
BRAXF Key Highlights
- Market Capitalization of 28K, indicating a micro-cap or early-stage public company valuation.
- Profit Margin of -697.5%, reflecting significant operating losses and investment in research and development.
- Gross Margin of 9.1%, demonstrating some revenue generation capability from its clinical services.
- Free Cash Flow (FCF) of $-0.00B, consistent with negative profitability and ongoing cash burn for operations and growth initiatives.
- Beta of 1.31, suggesting higher historical volatility relative to the overall market, common for biotechnology stocks.
Who Are BRAXF's Competitors?
BRAXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $21.82 | +4.45% | $1.93B | 79 |
| ANAB AnaptysBio, Inc. | $63.42 | -3.07% | $2.73B | 79 |
| ABVX Abivax S.A. | $144.65 | +9.12% | $9.48B | 76 |
| CGEN Compugen Ltd. | $2.28 | +7.04% | $215.58M | 76 |
| IVBXF Innovent Biologics, Inc. | $11.06 | +0.00% | $19.18B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| MIRM Mirum Pharmaceuticals, Inc. | $125.59 | +4.26% | $6.30B | 68 |
| BCYC Bicycle Therapeutics plc | $4.35 | +3.33% | $301.87M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BRAXF's Key Strengths?
- Integrated model combining clinical services with drug discovery and IP development.
- Focus on ketamine and psilocybin derivatives, addressing a growing market for novel mental health treatments.
- Established clinical operations providing direct patient care and valuable real-world data.
- Headquartered in Canada, potentially benefiting from evolving regulatory landscapes for psychedelics.
- Proprietary IP development platform for novel compounds and delivery methods.
What Are BRAXF's Weaknesses?
- Significant negative profit margin (-697.5%) and negative free cash flow, indicating substantial losses.
- Market capitalization of 28K, suggesting a very small or micro-cap valuation, potentially limiting access to capital.
- Reliance on the successful development and regulatory approval of novel drugs, which is a lengthy and high-risk process.
- Gross margin of 9.1% indicates limited profitability from current clinical operations.
- Unknown disclosure status on the OTC market, potentially impacting investor confidence and transparency.
What Could Drive BRAXF Stock Higher?
- Successful completion of clinical trials for novel ketamine or psilocybin derivatives, leading to positive data readouts and potential regulatory submissions.
- Expansion of the company's ketamine clinic network, increasing patient capacity and geographical reach to drive revenue growth.
- Formation of strategic partnerships or licensing agreements with larger pharmaceutical companies to accelerate drug development and commercialization.
- Continued development of proprietary intellectual property related to psychedelic compounds and advanced drug delivery methods, enhancing long-term asset value.
- Positive regulatory developments or increased acceptance of psychedelic-assisted therapies by health authorities, broadening market access.
What Are the Key Risks for BRAXF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant negative profit margin of -697.5% and negative free cash flow, indicating substantial financial losses and potential need for further capital raises.
- Failure to secure regulatory approvals for novel drug candidates, leading to delays or inability to commercialize research efforts.
- Intense competition within the biotechnology and mental health sectors, potentially impacting market share and pricing power for treatments and drugs.
- Adverse changes in regulatory frameworks or public perception regarding psychedelic-assisted therapies, affecting market growth and operational viability.
- Liquidity and volatility risks associated with trading on the 'OTC Other' tier, potentially hindering investor ability to trade shares efficiently.
What Are the Growth Opportunities for BRAXF?
- **Expansion of Ketamine Clinic Network:** The demand for alternative and effective treatments for depression and related disorders continues to grow, presenting a substantial market opportunity for Braxia Scientific's ketamine clinics. Expanding its geographical footprint and increasing the capacity of existing clinics could significantly boost revenue. The global depression treatment market is projected to reach tens of billions of dollars, with a segment dedicated to novel therapies like ketamine. This expansion could occur over the next 3-5 years, capitalizing on increasing patient and physician awareness of ketamine's therapeutic potential, particularly for treatment-resistant depression.
- **Development of Novel Psychedelic Derivatives:** Braxia Scientific's IP development platform is focused on creating ketamine and psilocybin derivatives. This research and development pipeline targets a potentially lucrative market for next-generation psychedelic therapeutics. As regulatory bodies like the FDA and Health Canada continue to evaluate these compounds, successful clinical trials and subsequent commercialization could unlock a multi-billion dollar market. The timeline for this opportunity is longer, likely 5-10 years, contingent on rigorous clinical development, regulatory approvals, and patent protection for proprietary formulations and delivery methods.
- **Commercialization of IP Development Platform:** Beyond specific drug candidates, the company's intellectual property platform itself represents a growth opportunity. This platform could be leveraged for partnerships, licensing agreements, or joint ventures with larger pharmaceutical companies seeking to enter or expand their presence in the psychedelic medicine space. Monetizing its research capabilities and proprietary knowledge could provide a non-dilutive source of capital and accelerate drug development. This could begin to materialize within the next 2-4 years as research progresses and specific IP assets become more defined and valuable.
- **Innovation in Drug Delivery Methods:** The development of novel drug delivery methods for ketamine, psilocybin, and their derivatives could significantly enhance patient experience, improve efficacy, and expand market access. Innovations such as sublingual films, nasal sprays, or sustained-release formulations could differentiate Braxia Scientific's products from competitors and address current limitations of existing treatments. The market for advanced drug delivery systems is substantial and constantly evolving. This area of growth could see developments within a 3-7 year timeframe, offering proprietary advantages and potentially higher margins.
- **Addressing Unmet Needs in Mental Health:** The global burden of mental health disorders, particularly depression, remains immense, with many patients not responding adequately to conventional treatments. Braxia Scientific's focus on novel therapies like ketamine and psychedelic derivatives directly addresses this significant unmet medical need. As awareness of treatment-resistant depression and the potential of these new therapies grows, Braxia Scientific is positioned to capture a share of this expanding patient population. This opportunity is ongoing, driven by continuous research, clinical evidence, and evolving medical guidelines.
What Opportunities Does BRAXF Have?
- Growing acceptance and research into psychedelic-assisted therapies for mental health disorders.
- Potential for expansion of ketamine clinics into new geographies or increased capacity in existing ones.
- Development and commercialization of proprietary ketamine and psilocybin derivatives with strong market potential.
- Strategic partnerships or licensing agreements with larger pharmaceutical companies for drug development and distribution.
- Innovation in drug delivery methods to improve patient outcomes and market differentiation.
What Threats Does BRAXF Face?
- Intense competition from other biotechnology companies and established pharmaceutical firms in mental health.
- Stringent and evolving regulatory hurdles for psychedelic compounds and their derivatives.
- High capital requirements for ongoing research, clinical trials, and clinic expansion.
- Potential for adverse public perception or stigma associated with psychedelic treatments.
- Market volatility and liquidity challenges associated with trading on the OTC market.
What Are BRAXF's Competitive Advantages?
- Proprietary intellectual property (IP) platform focused on novel ketamine and psilocybin derivatives, offering potential for unique drug candidates.
- Operational experience and established infrastructure in running specialized ketamine treatment clinics.
- Accumulated clinical data and expertise from direct patient care, informing research and development efforts.
- Early mover advantage in the emerging field of psychedelic-assisted therapies, particularly in Canada.
- Multidisciplinary approach combining clinical services with drug discovery, potentially creating synergistic benefits.
What Does BRAXF Do?
Braxia Scientific Corp., headquartered in Mississauga, Ontario, operates as a medical research company with a dual focus on clinical services and pharmaceutical development. The company's origins are rooted in addressing the significant unmet needs in mental healthcare, particularly for individuals suffering from depression and related disorders. Braxia Scientific has established and operates multidisciplinary clinics that provide ketamine treatments, a recognized therapeutic option for certain mental health conditions. This clinical arm serves as both a direct revenue stream and a practical environment for understanding patient needs and treatment efficacy. Beyond its clinical operations, Braxia Scientific is deeply engaged in research and development activities. Its core mission includes the discovery and commercialization of novel drugs and innovative delivery methods. A significant aspect of this involves leveraging its proprietary intellectual property (IP) development platform to create ketamine and psilocybin derivatives, alongside other psychedelic products. This strategic focus positions Braxia Scientific at the forefront of exploring the therapeutic potential of psychedelics, an area gaining increasing scientific and medical interest for its potential to revolutionize mental health treatment. The company's integrated approach, combining direct patient care with cutting-edge pharmaceutical research, aims to bridge the gap between scientific discovery and accessible, effective mental health solutions.
What Products and Services Does BRAXF Offer?
- Operates medical clinics specializing in ketamine treatments for individuals with depression and related mental health disorders.
- Conducts medical research aimed at discovering and commercializing novel drugs and drug delivery methods.
- Develops proprietary ketamine and psilocybin derivatives through its intellectual property (IP) development platform.
- Focuses on creating other psychedelic products from its research and development initiatives.
- Owns and manages multidisciplinary clinics designed for comprehensive mental health disorder treatment.
- Headquartered in Mississauga, Ontario, Canada, serving as its primary operational base.
How Does BRAXF Make Money?
- Generates revenue through the provision of ketamine treatments and other mental health services at its owned and operated clinics.
- Invests in research and development to discover and patent novel psychedelic compounds and delivery methods.
- Aims to commercialize proprietary drug candidates through potential licensing agreements, partnerships, or direct sales upon regulatory approval.
- Leverages its intellectual property platform to create a portfolio of assets in the psychedelic therapeutic space.
- Focuses on an integrated approach, combining clinical service delivery with pharmaceutical innovation.
What Industry Does BRAXF Operate In?
Braxia Scientific Corp. operates within the dynamic and rapidly evolving biotechnology industry, specifically focusing on mental health treatments. The broader healthcare sector is experiencing significant innovation, with a growing emphasis on personalized medicine and novel therapeutic approaches for neurological and psychiatric disorders. Braxia Scientific's positioning in the biotechnology sub-segment is characterized by its engagement in both clinical service delivery (ketamine clinics) and pharmaceutical research, particularly in the burgeoning field of psychedelic medicine. Market trends indicate increasing interest and investment in psychedelic-assisted therapies for conditions like depression, PTSD, and anxiety, driven by promising clinical trial results and a search for more effective treatments than traditional antidepressants. The competitive landscape includes established pharmaceutical companies, other biotech firms developing similar compounds, and a growing number of specialized clinics. Braxia Scientific aims to differentiate itself through its integrated approach, combining direct patient care with an IP development platform for next-generation therapeutics.
Who Are BRAXF's Key Customers?
- Individuals diagnosed with depression and related mental health disorders, particularly those seeking alternative or adjunctive treatments.
- Patients with treatment-resistant depression who may benefit from ketamine therapy.
- Healthcare providers and mental health professionals who refer patients for specialized treatments.
- Potential pharmaceutical partners interested in licensing or collaborating on novel psychedelic drug development.
- Researchers and academic institutions engaged in mental health and psychedelic studies.
F-Score 3/9Financial Health
Braxia Scientific Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BRAXF Valuation & Market Position
With a 28K market cap, Braxia Scientific Corp. sits in the micro-cap segment of the market. Relative to its peer group, BRAXF's quantitative score of 51/100 is below the peer average of 76/100.
Company Profile
Braxia Scientific Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Mississauga, CA. The company is led by CEO Peter Rizakos. BRAXF has traded publicly since 2020.
BRAXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Braxia's future, indicating that key executives believe in the company's potential.
- Community sentiment has shifted positively as discussions around mental health solutions gain traction, positioning Braxia favorably in an evolving market.
- New partnerships and collaborations have been announced, enhancing Braxia's reach and credibility in the psychedelic therapy space.
- Increased media coverage around psychedelic treatments is driving interest, which could lead to greater investor engagement and market momentum.
Bear Case
- Concerns over regulatory hurdles persist, as the psychedelic industry faces scrutiny that could delay product approvals and market entry.
- Recent discussions in the community highlight skepticism about the scalability of Braxia's business model and its ability to compete with larger players.
- Market perception remains cautious, with some investors wary of the volatility associated with emerging sectors like psychedelics.
- Insider selling activity has raised flags for some, suggesting that not all executives are fully confident in the company's short-term prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BRAXF Latest News
No recent news available for BRAXF.
BRAXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BRAXF.
Price Targets
Wall Street price target analysis for BRAXF.
BRAXF MoonshotScore
What does this score mean?
The MoonshotScore rates BRAXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Peter Rizakos
Unknown
Unknown. Specific career history, educational background, and previous roles for Peter Rizakos were not provided in the source data.
Track Record: Unknown. Key achievements, strategic decisions, and company milestones under Peter Rizakos's leadership were not provided in the source data.
BRAXF OTC Market Information
Braxia Scientific Corp. trades on the 'OTC Other' tier of the OTC market. This tier typically includes companies that do not meet the disclosure or financial standards for higher tiers like OTCQX or OTCQB, or that choose not to provide comprehensive financial disclosures. Companies in the 'OTC Other' category may have limited public information, making it more challenging for investors to conduct thorough due diligence. This tier is distinct from major exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial metrics, corporate governance, and minimum share prices, offering higher transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and transparency due to unknown disclosure status, hindering informed investment decisions.
- Lower liquidity and wider bid-ask spreads compared to major exchanges, potentially leading to difficulty in buying or selling shares.
- Increased price volatility due to smaller trading volumes and less stringent regulatory oversight.
- Higher susceptibility to manipulation and fraudulent activities due to less rigorous reporting requirements.
- Challenges in obtaining institutional investment and analyst coverage, limiting market visibility and investor interest.
- Verify the company's current financial statements and annual reports directly from official sources, if available.
- Research any recent news, press releases, or corporate actions that may not be widely disseminated.
- Investigate the company's management team and their track record beyond what is publicly stated.
- Assess the company's business model and competitive landscape thoroughly, given potential information gaps.
- Understand the regulatory environment specific to the company's operations and any pending changes.
- Evaluate the company's capital structure, outstanding shares, and potential for dilution.
- Consult with a financial advisor experienced in OTC markets to understand the specific risks.
- Operation of physical ketamine clinics, indicating tangible business activities and service delivery.
- Engagement in medical research and IP development, suggesting a commitment to innovation.
- Headquartered in Mississauga, Ontario, a recognized business hub, providing a physical presence.
- Publicly traded status, even on OTC, implies some level of corporate structure and reporting, however minimal.
- Focus on a legitimate and emerging medical field (psychedelic therapeutics for mental health).
What Investors Ask About Braxia Scientific Corp. (BRAXF) — Healthcare
What does Braxia Scientific Corp. do?
Braxia Scientific Corp. operates as a medical research company with a dual business model. Firstly, it owns and operates multidisciplinary clinics that provide ketamine treatments for individuals suffering from depression and related mental health disorders. This clinical arm offers direct patient care and generates service revenue. Secondly, the company is actively involved in research and development, focusing on discovering and commercializing novel drugs and delivery methods. A key part of this involves developing ketamine and psilocybin derivatives and other psychedelic products through its proprietary intellectual property development platform. Headquartered in Mississauga, Ontario, Braxia Scientific aims to innovate in the mental health treatment space by combining clinical practice with pharmaceutical research.
What are the main risks for BRAXF?
Braxia Scientific Corp. faces several significant risks. Financially, the company exhibits a substantial negative profit margin of -697.5% and negative free cash flow, indicating ongoing operational losses and a potential need for future capital raises, which could dilute existing shareholders. The success of its drug development efforts is highly uncertain, as clinical trials are lengthy, expensive, and often fail to yield regulatory approval. The company also operates in a highly competitive biotechnology landscape, with numerous firms vying for market share in mental health treatments. Furthermore, the regulatory environment for psychedelic-assisted therapies is still evolving, and adverse changes or public perception shifts could negatively impact its business. As an OTC-traded stock, it also carries risks related to lower liquidity, increased volatility, and less stringent disclosure requirements.
How does Braxia Scientific Corp. navigate regulatory approval processes for its treatments?
Braxia Scientific Corp. navigates regulatory approval processes by focusing its research and development on novel drug candidates, particularly ketamine and psilocybin derivatives, which are subject to rigorous evaluation by health authorities like Health Canada and potentially the FDA. While specific details on its regulatory track record or pending approvals are not provided, the company's engagement in IP development implies a strategy to develop proprietary compounds that would undergo preclinical testing, multiple phases of clinical trials, and ultimately seek market authorization. Compliance with Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) standards is essential for all stages of drug development. The company's clinical operations, providing ketamine treatments, operate within existing regulatory frameworks for approved therapies, ensuring adherence to current medical guidelines and safety protocols.
What are the key factors to evaluate for BRAXF?
Braxia Scientific Corp. (BRAXF) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does BRAXF data refresh on this page?
BRAXF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BRAXF's recent stock price performance?
Braxia Scientific Corp. (BRAXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated model combining clinical services with drug discovery and IP development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BRAXF overvalued or undervalued right now?
Valuing Braxia Scientific Corp. (BRAXF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BRAXF?
Before investing in Braxia Scientific Corp. (BRAXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Market capitalization and free cash flow are reported as $0.00B and $-0.00B respectively, which may indicate a very low value or rounding to zero for a micro-cap company. This has been stated as provided.
- Specific details regarding the CEO's background, track record, and title were not provided in the source data and are marked as 'Unknown'.
- No FMP PEER TICKERS were provided, so competitors are listed as 'Unknown'.
- The OTC disclosure status is 'Unknown' as per the source data, which impacts the depth of analysis for that section.
- No analyst ratings, price targets, or consensus information were provided, so the analyst FAQ was omitted as per instructions.